Alexander R. Cobitz
About
Alexander R. Cobitz is a scholar working on Hematology, Nephrology and Molecular Biology.
According to data from OpenAlex, Alexander R. Cobitz has authored 53 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 18 papers in Nephrology and 14 papers in Molecular Biology. Recurrent topics in Alexander R. Cobitz's work include Erythropoietin and Anemia Treatment (27 papers), Dialysis and Renal Disease Management (16 papers) and Iron Metabolism and Disorders (10 papers). Alexander R. Cobitz is often cited by papers focused on Erythropoietin and Anemia Treatment (27 papers), Dialysis and Renal Disease Management (16 papers) and Iron Metabolism and Disorders (10 papers). Alexander R. Cobitz collaborates with scholars based in United States, United Kingdom and India. Alexander R. Cobitz's co-authors include Brian Waterhouse, John J. Lepore, Christopher M. Ryan, Martin I. Freed, Mark W. J. Strachan, Delyth Jones, Brendan M. Johnson, Amy M. Meadowcroft, Louis Holdstock and Borut Čižman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American College of Cardiology and The Journal of Clinical Endocrinology & Metabolism.
In The Last Decade
Alexander R. Cobitz
53 papers receiving 1.5k citations
Peers
Alexander R. Cobitz
A. Kurtz Germany
Steven Harwood United Kingdom
Emil M. deGoma United States
Xiu Q. Wang United States
Ronald K. Mayfield United States
Markus Lassila Finland
James V. Gainer United States
Sachiko Hattori Japan
Winfried Maerz Germany
Frank Pistrosch Germany
Citations per year, relative to Alexander R. Cobitz Alexander R. Cobitz (= 1×)
peers
A. Kurtz
Countries citing papers authored by Alexander R. Cobitz
Since
Specialization
Citations
This map shows the geographic impact of Alexander R. Cobitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander R. Cobitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander R. Cobitz more than expected).
Fields of papers citing papers by Alexander R. Cobitz
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alexander R. Cobitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander R. Cobitz. The network helps show where Alexander R. Cobitz may publish in the future.
Co-authorship network of co-authors of Alexander R. Cobitz
This figure shows the co-authorship network connecting the top 25 collaborators of Alexander R. Cobitz. A scholar is included among the top collaborators of Alexander R. Cobitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander R. Cobitz. Alexander R. Cobitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hirschfield, Gideon M., Christopher L. Bowlus, David E.J. Jones, et al.. (2025). Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. The Lancet. Gastroenterology & hepatology. 11(1). 22–33.
2.
Macdougall, Iain C., Amy M. Meadowcroft, Borut Čižman, et al.. (2023). Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D). American Journal of Nephrology. 54(1-2). 1–13.
3.
Johansen, Kirsten L., Anjali Acharya, Borut Čižman, et al.. (2022). Challenges of Conducting Clinical Trials during the SARS-CoV-2 Pandemic: The ASCEND Global Program Experience. Kidney360. 3(4). 728–733.
4.
Singh, Ajay, Finnian R. Mc Causland, Brian Claggett, et al.. (2022). Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrology Dialysis Transplantation. 38(8). 1890–1897.
5.
Coyne, Daniel W., Ajay Singh, Renato D. Lópes, et al.. (2021). ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three Times Weekly in Hemodialysis Patients. Journal of the American Society of Nephrology. 32(10S). 191–191.
6.
Singh, Ajay, Borut Čižman, Alexander R. Cobitz, et al.. (2020). Regional Variation of Erythropoietin-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D). Journal of the American Society of Nephrology. 31(10S). 3–3.
7.
Tsubakihara, Yoshiharu, et al.. (2019). A 24‐Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients. Therapeutic Apheresis and Dialysis. 24(2). 108–114.
8.
Stirnadel-Farrant, Heide A., Angelo Karaboyas, Borut Čižman, et al.. (2019). Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions—A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney International Reports. 4(6). 864–872.
9.
Čižman, Borut, et al.. (2018). SaO004OCULAR SAFETY PROFILE OF DAPRODUSTAT: RESULTS OF TWO 24 WEEK STUDIES. Nephrology Dialysis Transplantation. 33(suppl_1). i316–i316.
10.
Stirnadel-Farrant, Heide A., Jiacong Luo, Lata Kler, et al.. (2018). Anemia and mortality in patients with nondialysis-dependent chronic kidney disease. BMC Nephrology. 19(1). 135–135.
11.
Akizawa, Tadao, Yoshiharu Tsubakihara, Masaomi Nangaku, et al.. (2016). Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. American Journal of Nephrology. 45(2). 127–135.
12.
Miller, Colin G., Antonio Nino, Allison R. Northcutt, et al.. (2016). Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint. Journal of Clinical Densitometry. 19(4). 485–491.
13.
Borges, João, John P. Bilezikian, Angela R. Jones-Leone, et al.. (2011). A randomized, parallel group, double‐blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long‐term glycaemic control and bone mineral density after 80 weeks of treatment in drug‐na ï ve type 2 diabetes mellitus patients. Diabetes Obesity and Metabolism. 13(11). 1036–1046.
14.
Davidson, J. K., Stephen McMorn, Barry D. Waterhouse, & Alexander R. Cobitz. (2007). A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in african american and hispanic american patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clinical Therapeutics. 29(9). 1900–1914.
15.
Rosenstock, J, et al.. (2006). Initial treatment with rosiglitazone/metformin fixed‐dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obesity and Metabolism. 8(6). 650–660.
16.
Rosenstock, Julio, et al.. (2006). Improvement in glycaemic control with rosiglitazone/metformin fixed‐dose combination therapy in patients with type 2 diabetes with very poor glycaemic control. Diabetes Obesity and Metabolism. 8(6). 643–649.
17.
Weissman, Peter N., et al.. (2005). Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Current Medical Research and Opinion. 21(12). 2029–2035.
18.
Brunzell, John D., Santica Marcovina, Dahong Yu, et al.. (2004). 1124-192 Rosiglitazone reduces novel biomarkers of cardiovascular disease in subjects with type 2 diabetes mellitus already on statin therapy. Journal of the American College of Cardiology. 43(5). A504–A504.
19.
Jucker, Beat M., et al.. (2003). Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: An in vivo nuclear magnetic resonance study. Metabolism. 52(2). 218–225.
20.
Tamanoi, Fuyuhiko, Eddy C. Hsueh, Laurie Goodman, et al.. (1988). Posttranslational modification of ras proteins: Detection of a modification prior to fatty acid acylation and cloning of a gene responsible for the modification. Journal of Cellular Biochemistry. 36(3). 261–273.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A. Kurtz Breakdown of academic impact, for papers by Steven Harwood Breakdown of academic impact, for papers by Emil M. deGoma Breakdown of academic impact, for papers by Xiu Q. Wang Breakdown of academic impact, for papers by Ronald K. Mayfield Breakdown of academic impact, for papers by Markus Lassila Breakdown of academic impact, for papers by James V. Gainer Breakdown of academic impact, for papers by Sachiko Hattori Breakdown of academic impact, for papers by Winfried Maerz Breakdown of academic impact, for papers by Frank Pistrosch